L
Linda Shurzinske
Researcher at Eli Lilly and Company
Publications - 8
Citations - 315
Linda Shurzinske is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Covariate & Dulaglutide. The author has an hindex of 4, co-authored 8 publications receiving 253 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo E. Umpierrez,Santiago Tofe Povedano,Federico Pérez Manghi,Linda Shurzinske,Valeria Pechtner +4 more
TL;DR: Dulaglutide improves glycemic control and is well tolerated as monotherapy in patients with early stage type 2 diabetes, and meets HbA1c targets.
Journal ArticleDOI
Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data
Honghua Jiang,Pandurang M. Kulkarni,Craig H. Mallinckrodt,Linda Shurzinske,Geert Molenberghs,Ilya Lipkovich +5 more
TL;DR: In this paper, a simulation study was conducted to quantify the magnitude of difference between the estimands underlying the two estimators in logistic regression, and the simulation results demonstrated that both unadjusted and adjusted analyses preserved Type I error at the nominal level.
Journal ArticleDOI
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis
Katherine R. Tuttle,Brian Rayner,Mark Lakshmanan,Anita Y.M. Kwan,Manige Konig,Linda Shurzinske,Fady T. Botros +6 more
TL;DR: Treatment with 1.5 mg DU weekly was associated with a clinically relevant risk reduction of ≥40% eGFR decline or ESKD compared with IG daily, particularly in the macroalbuminuria subgroup of participants with T2DM and moderate-to-severe CKD.
Journal ArticleDOI
To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest
Honghua Jiang,Pandurang M. Kulkarni,Craig H. Mallinckrodt,Linda Shurzinske,Geert Molenberghs,Ilya Lipkovich +5 more
TL;DR: Covariate adjusted methods improved power compared with the unadjusted methods because of the increased treatment effect estimates, especially when the correlation between the baseline and outcome was strong, even though there was an apparent increase in standard errors.
Journal ArticleDOI
Defining estimands using a mix of strategies to handle intercurrent events in clinical trials.
TL;DR: In this article, the authors proposed an estimand using a mix of strategies in handling intercurrent events (ICEs), which is an average of the "null" treatment difference for those with ICEs potentially related to safety and the treatment differences for the other patients if they would complete the assigned treatments.